Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.41 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9457628 | 0.95 | TSHR (0.53) | TSHRHSD17B10MMP12MMP13LOXL2 | |
| SCHEMBL6142005 | 0.90 | TSHR (0.49) | TSHRHSD17B10MMP12MMP13LOXL2 | |
| SCHEMBL7851897 | 0.90 | TSHR (0.49) | TSHRHSD17B10MMP12MMP13LOXL2 | |
| SCHEMBL2968409 | 0.89 | KCNJ1 (0.48) | TSHRHSD17B10MMP12MMP13LOXL2 | |
| SCHEMBL19599410 | 0.89 | TSHR (0.64) | TSHRHSD17B10MMP12MMP13LOXL2 | |
| SCHEMBL10341661 | 0.85 | TSHR (0.58) | TSHRHSD17B10MMP12MMP13LOXL2 | |
| SCHEMBL7851913 | 0.84 | KCNJ1 (0.44) | TSHRHSD17B10MMP12MMP13LOXL2 | |
| SCHEMBL16848648 | 0.82 | LOXL2 (0.58) | TSHRHSD17B10MMP12MMP13LOXL2 | |
| SCHEMBL14155434 | 0.82 | LOXL2 (0.58) | TSHRHSD17B10MMP12MMP13LOXL2 | |
| SCHEMBL20777022 | 0.81 | TSHR (0.41) | TSHRHSD17B10MMP12MMP13LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327741-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327741-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | TSHR 4461/4885HSD17B10 4543/4885MMP12 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.